A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism

Endocrinology

Volumn 149, Issue 12, 2008, Pages 5945-5950

  Neumann, Susanne ^a   Kleinau, Gunnar ^c   Costanzi, Stefano ^a   Moore, Susanna ^a   Jiang, Jian Kang ^b   Raaka, Bruce M ^a   Thomas, Craig J ^b   Krause, Gerd ^c   Gershengorn, Marvin C ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 (4 BROMOPHENYL) N TERT BUTYL 2(METHYLTHIO)THIENO[2,3 D]PYRIMIDINE 6 CARBOXAMIDE; ANTIBODY; ANTITHYROID AGENT; CEB 52; CHORIONIC GONADOTROPIN RECEPTOR; GONADORELIN DERIVATIVE; LUTEINIZING HORMONE RECEPTOR; MESSENGER RNA; ORG 41841; THYROID PEROXIDASE; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN; THYROTROPIN RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; EMBRYO; GRAVES DISEASE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPERTHYROIDISM; MOLECULAR MODEL; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA TRANSCRIPTION; THYMOCYTE; UPREGULATION;

ANTITHYROID AGENTS; CELL LINE; CELLS, CULTURED; COMPUTER SIMULATION; HUMANS; HYPERTHYROIDISM; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; RECEPTORS, THYROTROPIN;

EID: 57349112320     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-0836     Document Type: Article

References (29)

1. Ascoli M, Fanelli F, Segaloff DL 2002 The lutropin/ choriogonadotropin receptor, a 2002 perspective. Endocr Rev 23:141-174
2. Fan QR, Hendrickson WA 2005 Structure of human follicle-stimulating hormone in complex with its receptor. Nature 433:269-277
3. Szkudlinski MW, Fremont V, Ronin C, Weintraub BD 2002 Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. Physiol Rev 82:473-502
4. Vassart G, Pardo L, Costagliola S 2004 A molecular dissection of the glycoprotein hormone receptors. Trends Biochem Sci 29:119-126
5. Guo T 2005 Small molecule agonists and antagonists for the LH and FSH receptors. Expert Opin Ther Patents 15:1555-1564
6. Titus S, Neumann S, Zheng W, Southall N, Michael S, Klumpp C, Yasgar A, Shinn P, Thomas CJ, Inglese J, Gershengorn MC, Austin CP 2008 Quantitative high throughput screening using a live cell cAMP assay identifies small molecule agonists of the TSH receptor. J Biomol Screen 13:120-127
7. Jaschke H, Neumann S, Moore S, Thomas CJ, Colson AO, Costanzi S, Kleinau G, Jiang JK, Paschke R, Raaka BM, Krause G, Gershengorn MC 2006 A low molecular weight agonist signals by binding to the transmembrane domain of thyroid-stimulating hormone receptor (TSHR) and luteinizing hormone/chorionic gonadotropin receptor (LHCGR). J Biol Chem 281:9841-9844
8. Moore S, Jaeschke H, Kleinau G, Neumann S, Costanzi S, Jiang JK, Childress J, Raaka BM, Colson A, Paschke R, Krause G, Thomas CJ, Gershengorn MC 2006 Evaluation of small-molecule modulators of the luteinizing hormone/choriogonadotropin and thyroid stimulating hormone receptors: structure-activity relationships and selective binding patterns. J Med Chem 49:3888-3896
9. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC 2007 High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor. Science 318:1258 -1265
10. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VR, Sanishvili R, Fischetti RF, Schertler GF, Weis WI, Kobilka BK 2007 Crystal structure of the human β2 adrenergic G-protein-coupled receptor. Nature 450:383-387
11. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M 2000 Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289:739-745
12. Salom D, Lodowski DT, Stenkamp RE, Le Trong I, Golczak M, Jastrzebska B, Harris T, Ballesteros JA, Palczewski K 2006 Crystal structure of a photo-activated deprotonated intermediate of rhodopsin. Proc Natl Acad Sci USA 103:16123-16128
13. Standfuss J, Xie G, Edwards PC, Burghammer M, Oprian DD, Schertler GF 2007 Crystal structure of a thermally stable rhodopsin mutant. J Mol Biol 372:1179-1188
14. Aarons EJ, Beddows S, Willingham T, Wu L, Koup RA 2001 Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7. Virology 287:382-390
15. Dragic T, Trkola A, Lin SW, Nagashima KA, Kajumo F, Zhao L, Olson WC, Wu L, Mackay CR, Allaway GP, Sakmar TP, Moore JP, Maddon PJ 1998 Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J Virol 72:279-285
16. Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, Setoh P, Berg E, Liu G, Guy HR, Durell SR, Parmentier M, Chang CN, Price K, Tsang M, Doms RW 1999 Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem 274:9617-9626
17. Kleinau G, Claus M, Jaeschke H, Mueller S, Neumann S, Paschke R, Krause G 2007 Contacts between extracellular loop two and transmembrane helix six determine basal activity of the thyroid-stimulating hormone receptor. J Biol Chem 282:518-525
18. Case DA, Pearlman DA, Caldwell JW, Cheatham III TE, Wang J, Ross WS, Simmerling CL, Darden TA, Merz KM, Stanton RV, Cheng AL, Vincent JJ, Crowley M, Tsui V, Gohlke H, Radmer RJ, Duan Y, Pitera J, Massova I, Seibel GL, Singh UC, Weiner PK, Kollman PA 2002 AMBER 7 computer program. San Francisco: University of California, San Francisco
19. Laskowski RA, Moss DS, Thornton JM 1993 Main-chain bond lengths and bond angles in protein structures. J Mol Biol 231:1049-1067
20. Ballesteros JA, Weinstein H 1995 Integrated methods for the construction of three-dimensional models and computational probing of structure-function relationships in G-protein coupled receptors. Methods Neurosci. 25:366-428
21. McGovern SL, Caselli E, Grigorieff N, Shoichet BK 2002 A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem 45:1712-1722
22. Cavasotto CN, Orry AJ 2007 Ligand docking and structure-based virtual screening in drug discovery. Curr Top Med Chem 7:1006-1014
23. Congreve M, Murray CW, Blundell TL 2005 Structural biology and drug discovery. Drug Discov Today 10:895-907
24. Klebe G 2006 Virtual ligand screening: strategies, perspectives and limitations. Drug Discov Today 11:580-594
25. Marco E, Gago F 2007 Overcoming the inadequacies or limitations of experimental structures as drug targets by using computational modeling tools and molecular dynamics simulations. Chem Med Chem 2:1388-1401
26. Becker OM, Marantz Y, Shacham S, Inbal B, Heifetz A, Kalid O, Bar-Haim S, Warshaviak D, Fichman M, Noiman S 2004 G protein-coupled receptors: in silico drug discovery in 3D. Proc Natl Acad Sci USA 101:11304-11309
27. Klabunde T, Hessler G 2002 Drug design strategies for targeting G-protein-coupled receptors. Chembiochem 3:928-944
28. Schlegel B, Laggner C, Meier R, Langer T, Schnell D, Seifert R, Stark H, Holtje HD, Sippl W 2007 Generation of a homology model of the human histamine H(3) receptor for ligand docking and pharmacophore-based screening. J Comput Aided Mol Des 21:437-453
29. Tunaru S, Lattig J, Kero J, Krause G, Offermanns S 2005 Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A/PUMA-G). Mol Pharmacol 68:1271-1280